Surrozen (NASDAQ:SRZN) Major Shareholder Buys $91,356.69 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 4,271 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The stock was purchased at an average price of $21.39 per share, for a total transaction of $91,356.69. Following the completion of the transaction, the insider directly owned 639,141 shares in the company, valued at $13,671,225.99. This trade represents a 0.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were purchased at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The stock was purchased at an average price of $21.38 per share, for a total transaction of $15,628.78.

Surrozen Price Performance

Shares of NASDAQ SRZN traded up $0.98 during midday trading on Tuesday, reaching $23.08. 54,131 shares of the stock were exchanged, compared to its average volume of 146,533. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $24.94. The company has a market capitalization of $197.80 million, a price-to-earnings ratio of -1.03 and a beta of 0.58. The business has a 50-day simple moving average of $20.57 and a two-hundred day simple moving average of $15.04.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million during the quarter. Equities research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Large investors have recently bought and sold shares of the company. Stempoint Capital LP grew its stake in shares of Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Braidwell LP acquired a new position in Surrozen during the second quarter worth $1,252,000. Geode Capital Management LLC grew its position in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Stonepine Capital Management LLC increased its stake in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in Surrozen during the 3rd quarter worth about $621,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Finally, Wall Street Zen raised shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.